

IDS - 06/11/2002

COPY OF PAPERS
ORIGINALLY FILED

1633
Atty. Dkt. No. 047940-0135



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Harvey D. PREISLER

Title: BINDING-SPECIFIC PEPTIDES,
BINDING-SPECIFIC CARRIER
MOLECULES, AND USES THEREOF

Appl. No.: 10/062,587

Filing Date: 1/31/02

Art Unit: 1633

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below. Robert N. Young (Printed Name) (Signature) June 5, 2002 (Date of Deposit)
--

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JUN 14 2002
TECH CENTER 1600/2002

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



COPY OF PAPERS
ORIGINALLY FILED

Atty. Dkt. No. 047940-0135

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 06-1447. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1447.

Respectfully submitted,

Date June 5, 2002

By 

FOLEY & LARDNER
Customer Number: 23524




23524

PATENT TRADEMARK OFFICE

Telephone: (608) 258-4991

Facsimile: (608) 258-4258

Robert N. Young
Attorney for Applicant
Registration No. 48,412



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 2

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		047940-0135	10/062,587
		APPLICANT Harvey D. PREISLER	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		FILING DATE 01/31/2002	GROUP ART UNIT 1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
KAC		5,512,435	4/30/96	Renschler <i>et al.</i>			

RECEIVED

JUN 14 2002


TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	✓	A. Cabibbo <i>et al.</i> , "Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix," <u>Gene</u> 167, pp. 41-47, 1995; published by Elsevier Science B.V.
	✓	M. A. Barry <i>et al.</i> , "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries," <u>Nature Medicine</u> 2(3), pp. 299-305, March 1996.
	✓	R. Pasquallini and E. Ruoslahti, "Organ targeting <i>in vivo</i> using phage display peptide libraries," <u>Nature</u> 380, pp. 364-366, 1996.
	✓	J. W. Smith and E. Ruoslahti, "Harvesting Molecular Diversity - Biology's New Commodity," <u>Biotech Gen Eng Rev</u> 14, pp. 51-65, April 1997.
	✓	M. Szardenings <i>et al.</i> , "Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1," <u>J Biol Chem</u> 272(44), pp.27943-27948, 1997; published by The American Society for Biochemistry and Molecular Biology, Inc.
	✓	W. Arap <i>et al.</i> , "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <u>Science</u> 279, pp. 377-380, January 1998.
	✓	W. Arap <i>et al.</i> , "Chemotherapy targeted to tumor vasculature," <u>Curr Opin Oncol</u> 10, pp. 560-565, 1998.



KAC	✓	T. Samoylova and B. F. Smith, "Elucidation of muscle-binding peptides by phage display screening," <u>Muscle and Nerve</u> , pp. 460-466, April 1999.
	✓	J. D. Norris <i>et al.</i> , "Peptide antagonists of the human estrogen receptor," <u>Science</u> 285, pp. 744-746, July 1999.
	✓	V. V. Ivanenkov <i>et al.</i> , "Targeted delivery of multivalent phage display vectors into mammalian cells," <u>Biochimica et Biophysica Acta</u> 1448, pp. 463-472, 1999; published by Elsevier Science B.V.
	✓	E. Koivunen <i>et al.</i> , "Identification of receptor ligands with phage display peptide libraries," <u>J Nucl Med</u> 40, pp. 883-888, 1999.
	✓	L. Mazzucchelli <i>et al.</i> , "Cell-specific peptide binding by human neutrophils," <u>Blood</u> 93, pp. 1738-1748, 1999.
	✓	D. J. Rodi and L. Makowski, "Phage-display technology - finding a needle in a vast molecular haystack," <u>Curr Opin Biotechnol</u> 10(1), pp. 87-93, 1999; published by Elsevier Science B.V.
	✓	K. C. Brown, "New approaches for cell-specific targeting: Identification of cell-selective peptides from combinatorial libraries," <u>Curr Opin Chem Biol</u> 4, pp. 16-21, 2000; published by Elsevier Science B.V.
	✓	F. D. Hong and G. L. Clayman, "Isolation of a peptide for targeted drug delivery into human head and neck solid tumors," <u>Cancer Res</u> 60, pp. 6551-6556, December 2000.
EXAMINER		DATE CONSIDERED
/Karen A. Canella, Ph.D./		12/26/2006
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.		